TY - JOUR
T1 - Consequences of anorectal cancer atlas implementation in the cooperative group setting
T2 - Radiobiologic analysis of a prospective randomized in silico target delineation study
AU - Mavroidis, Panayiotis
AU - Giantsoudis, Drosoula
AU - Awan, Musaddiq J.
AU - Nijkamp, Jasper
AU - Rasch, Coen R.N.
AU - Duppen, Joop C.
AU - Thomas, Charles R.
AU - Okunieff, Paul
AU - Jones, William E.
AU - Kachnic, Lisa A.
AU - Papanikolaou, Niko
AU - Fuller, Clifton D.
N1 - Funding Information:
C.D.F. received support from the Hope Foundation /Southwest Oncology Group Dr. Charles A. Coltman, Jr. Fellowship in Clinical Trials and the National Institutes of Health Clinician Scientist Loan Repayment Program (L30 CA136381-01). CDF has served as consultant for GE Medical Systems, Inc. These funders played no role in the study design, collection, analysis, interpretation of data, manuscript writing, or decision to submit the report for publication. Portions of the data were selected for a poster presentation at ESTRO 31, May 9–12, Barcelona, Spain.
Publisher Copyright:
© 2014 Elsevier Ireland Ltd. All rights reserved.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Purpose The aim of this study is to ascertain the subsequent radiobiological impact of using a consensus guideline target volume delineation atlas. Materials and methods Using a representative case and target volume delineation instructions derived from a proposed IMRT rectal cancer clinical trial, gross tumor volume (GTV) and clinical/planning target volumes (CTV/PTV) were contoured by 13 physician observers (Phase 1). The observers were then randomly assigned to follow (atlas) or not-follow (control) a consensus guideline/atlas for anorectal cancers, and instructed to re-contour the same case (Phase 2). Results The atlas group was found to have increased tumor control probability (TCP) after the atlas intervention for both the CTV (p < 0.0001) and PTV1 (p = 0.0011) with decreasing normal tissue complication probability (NTCP) for small intestine, while the control group did not. Additionally, the atlas group had reduced variance in TCP for all target volumes and reduced variance in NTCP for the bowel. In Phase 2, the atlas group had increased TCP relative to the control for CTV (p = 0.03). Conclusions Visual atlas and consensus treatment guideline usage in the development of rectal cancer IMRT treatment plans reduced the inter-observer radiobiological variation, with clinically relevant TCP alteration for CTV and PTV volumes.
AB - Purpose The aim of this study is to ascertain the subsequent radiobiological impact of using a consensus guideline target volume delineation atlas. Materials and methods Using a representative case and target volume delineation instructions derived from a proposed IMRT rectal cancer clinical trial, gross tumor volume (GTV) and clinical/planning target volumes (CTV/PTV) were contoured by 13 physician observers (Phase 1). The observers were then randomly assigned to follow (atlas) or not-follow (control) a consensus guideline/atlas for anorectal cancers, and instructed to re-contour the same case (Phase 2). Results The atlas group was found to have increased tumor control probability (TCP) after the atlas intervention for both the CTV (p < 0.0001) and PTV1 (p = 0.0011) with decreasing normal tissue complication probability (NTCP) for small intestine, while the control group did not. Additionally, the atlas group had reduced variance in TCP for all target volumes and reduced variance in NTCP for the bowel. In Phase 2, the atlas group had increased TCP relative to the control for CTV (p = 0.03). Conclusions Visual atlas and consensus treatment guideline usage in the development of rectal cancer IMRT treatment plans reduced the inter-observer radiobiological variation, with clinically relevant TCP alteration for CTV and PTV volumes.
KW - Anorectal cancer
KW - Atlas implementation
KW - Inter-observer variation
KW - Radiobiological analysis
KW - Target delineation
UR - http://www.scopus.com/inward/record.url?scp=84911006491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84911006491&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2014.05.011
DO - 10.1016/j.radonc.2014.05.011
M3 - Article
C2 - 24996454
AN - SCOPUS:84911006491
SN - 0167-8140
VL - 112
SP - 418
EP - 424
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 3
ER -